Table 1.
Baseline data of patients included in the study.
| Characteristics | TACE | TACE+TKI | TACE+TKI+ICIs | χ²value | P value |
|---|---|---|---|---|---|
| number | 45 | 76 | 50 | ||
| Gender,n (%) | 0.285 | 0.867 | |||
| Male | 38 (84.4) | 65 (85.5) | 41 (82.0) | ||
| Female | 7 (15.6) | 11 (14.5) | 9 (18.0) | ||
| Age (years),n (%) | 0.62 | 0.733 | |||
| <60 | 26 (57.8) | 42 (55.3) | 25 (50.0) | ||
| ≥60 | 19 (42.2) | 34 (44.7) | 25 (50.0) | ||
| ECOG-PS,n (%) | 2.464 | 0.292 | |||
| 0-1 | 28 (62.2) | 55 (72.4) | 30 (60.0) | ||
| 2 | 17 (37.8) | 21 (27.6) | 20 (40.0) | ||
| Child-Pugh class,n (%) | 4.942 | 0.085 | |||
| A | 26 (57.8) | 55 (72.4) | 39 (78.0) | ||
| B | 19 (42.2) | 21 (27.6) | 11 (22.0) | ||
| BCLC,n (%) | 0.068 | 0.967 | |||
| Stage A+B | 30 (66.7) | 49 (64.5) | 33 (66.0) | ||
| Stage C | 15 (33.3) | 27 (35.5) | 17 (34.0) | ||
| Portal vein tumor thrombus,n (%) | 0.304 | 0.859 | |||
| Yes | 14 (31.1) | 27 (35.5) | 16 (32.0) | ||
| No | 31 (68.9) | 49 (64.5) | 34 (68.0) | ||
| Tumor number,n (%) | 4.99 | 0.083 | |||
| Single | 20 (44.4) | 21 (27.6) | 22 (44.0) | ||
| Multiple | 25 (55.6) | 55 (72.4) | 28 (56.0) | ||
| Tumor size (cm),n (%) | 0.924 | 0.63 | |||
| <10 | 23 (51.1) | 40 (52.6) | 30 (60.0) | ||
| ≥10 | 22 (48.9) | 36 (47.4) | 20 (40.0) | ||
| Hepatitis B virus,n (%) | 3.447 | 0.178 | |||
| + | 35 (77.8) | 68 (89.5) | 44 (88.0) | ||
| - | 10 (22.2) | 8 (10.5) | 6 (12.0) | ||
| AFP (ng/ml),n (%) | 1.913 | 0.384 | |||
| <400 | 22 (48.9) | 33 (43.4) | 28 (56.0) | ||
| ≥400 | 23 (51.1) | 43 (56.6) | 22 (44.0) | ||
| ALT (U/L),n (%) | 0.103 | 0.95 | |||
| <40 | 22 (48.9) | 35 (46.1) | 24 (48.0) | ||
| ≥40 | 23 (51.1) | 41 (53.9) | 26 (52.0) | ||
| NLR,n (%) | 5.091 | 0.078 | |||
| <2.195 | 14 (31.1) | 32 (42.1) | 27 (54.0) | ||
| ≥2.195 | 31 (68.9) | 44 (57.9) | 23 (46.0) |
TACE, transcatheter arterial chemoembolization; TKI, tyrosine kinase inhibitors; ICIs, immune checkpoint inhibitors; ECOG-PS, Eastern Cooperative Oncology Group performance status; BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; ALT, alamine aminotransferase; NLR, neutrophil-lymphocyte ratio